TerminatedPhase 1NCT01795313

Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod

Studying Ependymoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
James Felker
Principal Investigator
James Felker, MD
University of Pittsburgh
Intervention
HLA-A2 restricted synthetic tumor antigen(biological)
Enrollment
23 enrolled
Eligibility
21 years · All sexes
Timeline
20122025

Study locations (1)

Collaborators

Solving Kids' Cancer · National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01795313 on ClinicalTrials.gov

Other trials for Ependymoma

Additional recruiting or active studies for the same condition.

See all trials for Ependymoma

← Back to all trials